The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Gilead Sciences' 2013 sales performance.
Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group
The European Medicines Agency (EMA) has begun an accelerated review of Gilead’s Trodelvy for the treatment of advanced triple-negative breast cancer. ... Gilead is also testing Trodelvy’s potential in non-small cell lung cancer and metastatic
and running, ahead of our UK marketing authorisation in IBD, through our partnership with Gilead. ... With a focus on inflammatory and fibrotic conditions, we have submitted a marketing application through our partnership with Gilead for a new treatment
The two companies first announced their NASH collaboration in 2019. Gilead and Novo Nordisk have planned a new phase 2b trial in a bid to expand their clinical collaboration in ... The two companies first announced their collaboration in 2019, focused on
First CAR-T cell therapy to be approved in this indication. Gilead subsidiary Kite's Yescarta has been granted accelerated approval from the US Food and Drug Administration (FDA) for indolent
We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...